8-K: Medpace Holdings Reports Strong Q2 2026 Financial Results

Medpace Holdings, Inc. announced robust second quarter 2026 financial results, with significant year-over-year growth in revenue, net income, and EBITDA, alongside strong new business awards.

Summary

• Medpace Holdings, Inc. reported second quarter 2026 revenue of $707.3 million, a 17.2% increase from $603.3 million in the prior year period.
• Net new business awards reached $795.7 million, up 28.2% from $620.5 million in Q2 2025, resulting in a net book-to-bill ratio of 1.13x.
• GAAP net income for the quarter was $121.4 million ($4.25 per diluted share), compared to $90.3 million ($3.10 per diluted share) in Q2 2025.
• EBITDA for the second quarter of 2026 was $153.4 million, a 17.6% increase from $130.5 million in the prior year period.
• Backlog as of June 30, 2026, grew to $3,014.2 million, a 4.9% increase year-over-year.
• The company generated $162.0 million in cash flow from operating activities in Q2 2026 and repurchased $294.7 million of its stock.
• Full-year 2026 revenue is forecasted between $2.805 billion and $2.885 billion, with GAAP net income projected at $494.0 million to $514.0 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant year-over-year growth across key financial metrics and a healthy outlook, indicating robust business performance and market position.

Positives

• Revenue increased by 17.2% to $707.3 million in Q2 2026 compared to Q2 2025.
• Net new business awards grew by 28.2% to $795.7 million in Q2 2026, indicating strong demand for services.
• Net book-to-bill ratio of 1.13x signifies that new business awards exceeded revenue recognized.
• GAAP net income surged by 34.5% to $121.4 million in Q2 2026.
• Diluted EPS increased to $4.25 from $3.10 in the prior year period.
• EBITDA rose by 17.6% to $153.4 million in Q2 2026.
• EBITDA margin remained strong at 21.7% in Q2 2026.
• Backlog increased by 4.9% to $3,014.2 million as of June 30, 2026.

Negatives

• Total direct costs increased by 19.5% to $505.7 million in Q2 2026 from $423.3 million in Q2 2025, outpacing revenue growth slightly.
• Selling, general and administrative (SG&A) expenses increased to $48.1 million from $46.7 million, though at a slower pace than revenue.
• Accumulated deficit was $(511,368) thousand as of June 30, 2026.

Risks

• Potential loss, delay, or non-renewal of contracts, or non-payment by customers.
• Failure to convert backlog to revenue at historical rates.
• Inability to maintain or generate new business awards.
• Fluctuations in results between fiscal quarters and years.
• Risks related to pandemics, epidemics, or widespread health emergencies impacting business operations.
• Increased pricing pressure leading to decreased operating margins.
• Failure to perform services in accordance with contractual requirements, regulations, and ethical standards.
• Risks associated with cybersecurity breaches and disruptions to information systems.

Future Outlook

The company forecasts 2026 revenue between $2.805 billion and $2.885 billion, representing 10.9% to 14.0% growth over 2025. Full-year GAAP net income is projected at $494.0 million to $514.0 million, and EBITDA is expected to be between $618.0 million and $642.0 million. Diluted EPS is forecasted to be in the range of $17.25 to $17.95.

Management Comments

• Medpace Holdings, Inc. (Nasdaq: MEDP) (Medpace) today announced financial results for the second quarter ended June 30, 2026.
• The company's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.

Industry Context

StockSavvy.ai notes that Medpace's strong Q2 2026 performance, particularly its revenue and net new business growth, aligns with the increasing demand for outsourced clinical research services driven by pharmaceutical and biotechnology companies' R&D pipelines. The robust book-to-bill ratio suggests continued expansion opportunities in a competitive CRO market.

Comparison to Industry Standards

• Medpace's revenue growth of 17.2% in Q2 2026 and 17.2% on a constant currency basis exceeds the typical growth rates seen in many mature industries, reflecting the dynamic nature of the CRO sector.
• The net book-to-bill ratio of 1.13x is a strong indicator within the CRO industry, suggesting healthy future revenue potential.
• EBITDA margins of 21.7% are generally considered strong for a service-based organization, particularly in the complex and regulated CRO space, where margins can be impacted by project complexity and regulatory compliance costs.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, and continued share repurchase program, potentially leading to increased shareholder value.
• Employees: Continued growth and strong financial results may lead to job security and potential for bonuses or incentives.
• Customers: Continued provision of high-quality clinical development services, supporting their drug and device development pipelines.
• Suppliers: Continued business operations and potential for increased service demand.

Next Steps

• Medpace will host a conference call on July 23, 2026, to discuss its second quarter 2026 results.
• The company will continue to execute its growth strategies and manage its operations to achieve its full-year guidance.

Key Dates

Recommendation

The company demonstrated exceptional growth in revenue, net income, and new business awards, significantly exceeding prior year performance. The strong backlog and positive full-year guidance indicate sustained momentum. The share repurchase program further enhances shareholder value. These factors collectively suggest a compelling investment opportunity.

Keywords

Clinical Research Organization, CRO, Drug Development, Biotechnology, Pharmaceutical, Medical Device, Clinical Trials, Revenue Growth